Lot certificates published
Plain, secure packaging

same family

Tesamorelin vs Sermorelin

The stored sermorelin sequence matches the first 29 residues of tesamorelin’s 44-residue GRF backbone. Their chain lengths and recorded terminal features differ.

Published: 2026-10-03Library record comparison: 2026-10-03

01

Identity side by side

Recorded molecular identities of Tesamorelin and Sermorelin
Recorded fieldTesamorelinSermorelin
Canonical nameTesamorelinSermorelin
Aliasesnot recordedGRF(1-29); Sermorelina; Sermorelinum
Development codesTH9507not recorded
CAS218949-48-586168-78-7
UNIIMQG94M5EEO89243S03TE
PubChem CID1613782816132413
Molecular formulaC221H366N72O67SC149H246N44O42S
Molecular weight (Da)5135.93357.9
Sequence length (residues)4429
Terminal modificationsN-terminal trans-3-hexenoyl at Tyr1; C-terminal amide at Leu44Free N-terminus; C-terminal amide at Arg29
Structural modificationsnot recordednot recorded

Tesamorelin: nomenclature notes

Development code TH9507 appears in the PubChem synonym set and in the contemporaneous literature. A second registry number, 804475-66-9, also appears in the PubChem record; 218949-48-5 is carried here as primary.

Sermorelin: nomenclature notes

Sermorelin corresponds to residues 1 to 29 of human growth hormone-releasing factor, the fragment commonly written GRF(1-29). Two related entries are in this library. CJC-1295 is a tetrasubstituted analog of this fragment; the form bearing an added C-terminal maleimidopropionamide lysine, which enables albumin conjugation, is a separate species from the one the CJC-1295 entry describes. Tesamorelin is not a derivative of the fragment: it is the full 44-residue sequence, of which this fragment is the first 29 residues, carrying an N-terminal hexenoyl group and a C-terminal amide.

02

Residue sequence comparison

Positions are numbered from each stored sequence’s first residue. Highlighted cells differ or extend beyond the other chain; a dash indicates no aligned residue. One-letter notation does not encode terminal groups or stereochemistry. Read the recorded notes below.

Aligned one-letter residue sequences
Tesamorelin1Y2A3D4A5I6F7T8N9S10Y11R12K13V14L15G16Q17L18S19A20R21K22L23L24Q25D26I27M28S29R30Q31Q32G33E34S35N36Q37E38R39G40A41R42A43R44L
Sermorelin1Y2A3D4A5I6F7T8N9S10Y11R12K13V14L15G16Q17L18S19A20R21K22L23L24Q25D26I27M28S29R·—·—·—·—·—·—·—·—·—·—·—·—·—·—·—

Differences in the one-letter sequence

  • Tesamorelin: residue 30 = Q; Sermorelin: no aligned residue.
  • Tesamorelin: residue 31 = Q; Sermorelin: no aligned residue.
  • Tesamorelin: residue 32 = G; Sermorelin: no aligned residue.
  • Tesamorelin: residue 33 = E; Sermorelin: no aligned residue.
  • Tesamorelin: residue 34 = S; Sermorelin: no aligned residue.
  • Tesamorelin: residue 35 = N; Sermorelin: no aligned residue.
  • Tesamorelin: residue 36 = Q; Sermorelin: no aligned residue.
  • Tesamorelin: residue 37 = E; Sermorelin: no aligned residue.
  • Tesamorelin: residue 38 = R; Sermorelin: no aligned residue.
  • Tesamorelin: residue 39 = G; Sermorelin: no aligned residue.
  • Tesamorelin: residue 40 = A; Sermorelin: no aligned residue.
  • Tesamorelin: residue 41 = R; Sermorelin: no aligned residue.
  • Tesamorelin: residue 42 = A; Sermorelin: no aligned residue.
  • Tesamorelin: residue 43 = R; Sermorelin: no aligned residue.
  • Tesamorelin: residue 44 = L; Sermorelin: no aligned residue.

Further differences are recorded in the sequence notes.

Tesamorelin

Terminal modifications
N-terminal trans-3-hexenoyl at Tyr1; C-terminal amide at Leu44
Structural modifications
not recorded
Stored three-letter notation
Tyr · Ala · Asp · Ala · Ile · Phe · Thr · Asn · Ser · Tyr · Arg · Lys · Val · Leu · Gly · Gln · Leu · Ser · Ala · Arg · Lys · Leu · Leu · Gln · Asp · Ile · Met · Ser · Arg · Gln · Gln · Gly · Glu · Ser · Asn · Gln · Glu · Arg · Gly · Ala · Arg · Ala · Arg · Leu
Sequence notes
The full 44-residue human growth hormone-releasing factor sequence, carried with a hexenoyl cap on Tyr1 and a C-terminal amide on Leu44. Sermorelin, also in this library, is the first 29 residues of this same sequence, without the hexenoyl cap and carried as a C-terminal amide at Arg29. The recorded formula and mass are the values this sequence derives with both caps applied; without the hexenoyl the derivation falls 96.13 Da short, which is why the cap is declared rather than described only in prose.

Sermorelin

Terminal modifications
Free N-terminus; C-terminal amide at Arg29
Structural modifications
not recorded
Stored three-letter notation
Tyr · Ala · Asp · Ala · Ile · Phe · Thr · Asn · Ser · Tyr · Arg · Lys · Val · Leu · Gly · Gln · Leu · Ser · Ala · Arg · Lys · Leu · Leu · Gln · Asp · Ile · Met · Ser · Arg
Sequence notes
The N-terminal 29 residues of human growth hormone-releasing hormone, carried as a C-terminal amide. The recorded molecular formula and mass are the values this sequence derives with that amide applied; without it the derivation gives the free acid and does not match. The IUPHAR/BPS Guide to Pharmacology (ligand 6998, release 2026.3.1) prints a thirty-residue sermorelin sequence ending Gln30; this record keeps the twenty-nine-residue fragment ending in Arg29 amide, matching PubChem CID 16132413.

03

Recorded mechanisms

These lists show the links recorded in each monograph. An unlisted link does not establish its absence from the molecule’s biology.

Shared recorded links

Recorded only for Tesamorelin

not recorded

Recorded only for Sermorelin

not recorded

04

Recorded compound classes

Shared recorded links

Recorded only for Tesamorelin

not recorded

Recorded only for Sermorelin

not recorded

05

References for the relationship

  1. Reference 1

    Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor.

    Tomlinson B

    Current opinion in investigational drugs (London, England : 2000) · 2006-10 · Review

    current
  2. Reference 2

    PEGylation of growth hormone-releasing hormone (GRF) analogues.

    Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM

    Advanced drug delivery reviews · 2003-09-26 · Review

    current

Study models of these references

What kind of experiment each cited paper reports, taken from its abstract unless marked. Not a summary of results.

ReferenceStudy models
Tomlinson B 2006Review article
Esposito P et al. 2003Review article

06

Read the full monographs